Watson Laboratories to market PregLem's Esmya in North America
This article was originally published in Scrip
Executive Summary
Watson Laboratories, part of Watson Pharmaceuticals, has signed an agreement with Gedeon Richter's newly acquired subsidiary in Switzerland, PregLem, to develop and market PregLem's treatment of uterine fibroids Esmya (ulipristal acetate) in the US and Canada.